White & Case (Washington)

Adam Acosta

White & Case (Washington)
Lawyer (Associate)

Adam Acosta is an associate in the Firm’s Global Antitrust and Competition Practice. His practice focuses on antitrust litigation, government investigations, and related counseling. Mr. Acosta represents clients in a wide range of industries and frequently represents clients in the pharmaceutical industry with cases involving allegations of reverse payment settlements and product hopping. Prior to joining White & Case, Mr. Acosta completed a two-year clerkship in the US District Court for the Southern District of Indiana. He currently serves as an elected board member for the Hispanic Bar Association of DC and is active in the American Bar Association’s Antitrust Section.

Distinctions

Linked authors

White & Case (New York)
White & Case (Washington)
White & Case (New York)

Articles

261 Bulletin

Bryan D. Gant, Eric Grannon, Adam Acosta The US District Court for the District of Delaware contradicts the Supreme Court precedent regarding patent settlements in the pharmaceutical sector (Chimicles Schwartz Kriner / Donaldson-Smith / Amgen / Teva / Watson / Actavis)

44

A Nov. 30 decision by the U.S. District Court for the District of Delaware, In re: Sensipar Antitrust Litigation, contradicts controlling U.S. Supreme Court precedent and, if followed, could have significant implications for patent settlements well outside the pharmaceutical context in which it (...)

Adam Acosta, Eric Grannon The US FTC and the FDA issue a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive practices in the biologic marketplace

79

On February 3, 2020, the Federal Trade Commission ("FTC") and the Food and Drug Administration ("FDA") issued a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive practices in the "biologic marketplace." As discussed below, the FTC and (...)

Send a message